C8 dihydro Ceramide (d18:0/8:0)
(Synonyms: Cer(d18:0/8:0)) 目录号 : GC43108A sphingolipid
Cas No.:145774-33-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C8 dihydro Ceramide is a sphingolipid and an intermediate in the synthesis of C8 ceramide [1]. It is synthesized by the acylation of sphinganine by ceramide synthase, a process that can be inhibited by some fungal mycotoxins, such as fumonisin B1 . [2] C8 dihydro Ceramide can be converted to C8 ceramide via the introduction of a 4,5-trans double bond by dihydroceramide desaturase.[1]C8 dihydro ceramide is metabolically inactive and has been used as a negative control for the biological activity of C8 ceramide.[3]
Reference:
[1]. Michel, C., van Echten-Deckert, G., Rother, J., et al. Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. 272(36), 22432-22437 (1997).
[2]. Wang, E., Norred, W.P., Bacon, C.W., et al. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J. Biol. Chem. 266(22), 14486-14490 (1991).
[3]. Struckhoff, A.P., Bittman, R., Burow, M.E., et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther. 309(2), 523-532 (2004).
| Cas No. | 145774-33-0 | SDF | |
| 别名 | Cer(d18:0/8:0) | ||
| 化学名 | N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-octanamide | ||
| Canonical SMILES | O=C(CCCCCCC)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC | ||
| 分子式 | C26H53NO3 | 分子量 | 427.7 |
| 溶解度 | Chloroform: Soluble,DMSO: Soluble,Ethanol: Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3381 mL | 11.6904 mL | 23.3809 mL |
| 5 mM | 0.4676 mL | 2.3381 mL | 4.6762 mL |
| 10 mM | 0.2338 mL | 1.169 mL | 2.3381 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet